Freenome (FRNM) Q4 2024 earnings summary

Executive summary

• Incorporated in March 2024 as a blank check company (SPAC) focused on healthcare/life sciences business combinations; no operating revenues to date and activities limited to organizational matters and identifying acquisition targets.

• Completed IPO on June 13, 2024, raising $86.25 million through 8,625,000 Class A shares at $10.00 each, plus $2.86 million from a private placement; proceeds placed in a trust account for future business combination.

• Management team and sponsor have extensive experience in healthcare investments and prior SPAC transactions; targeting North American and European life sciences and medical technology companies.

Financial highlights

• As of December 31, 2024, $88.65 million held in trust account, including $2.37 million interest income and $38,396 unrealized gain.

• Net income for the period from inception to December 31, 2024, was $1.91 million, driven by interest income; operating expenses totaled $494,005.

• Working capital as of year-end was $1.03 million; cash outside the trust account was $1.13 million.

• No operating revenues; all income derived from interest on trust account investments.

Outlook and guidance

• No assurance of completing a business combination; must complete one or more business combinations with an aggregate fair market value of at least 80% of net assets in trust within 24 months of IPO (by June 2026) or redeem public shares and liquidate.

• May seek additional financing or issue equity/debt to complete a business combination if needed.

• Sponsor has indicated interest in purchasing up to $25 million of Class A shares in a private placement concurrent with the business combination, but this is non-binding.